Study of HLX3901 for advanced lung or neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced small cell lung cancer or neuroendocrine cancer that got worse after standard treatments.
- You need at least one tumor that can be measured on a scan.
- You should be able to take care of yourself (ECOG score 0 or 1).
- You must agree to provide a tumor sample (from a past surgery or new biopsy) for testing.
- You must have adequate organ function and no serious heart problems or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Hear when a new NEC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.